Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2191 to 2200 of 2579 total matches.
Removable Permanent Tattoo Ink
The Medical Letter on Drugs and Therapeutics • Sep 10, 2007 (Issue 1269)
and about one quarter of those aged 18-50 now have at
least one tattoo.
1
In later life, some people come ...
In the US, over one third of adults under the age of 35 and about one quarter of those aged 18-50 now have at least one tattoo. In later life, some people come to regret their tattoos, but tattoo inks can be difficult and expensive to remove.2 Recently, some new tattoo inks have been designed for improved safety and ease of removal.
Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
) Inhibitors
Adalimumab3 – Humira
(Abbvie)
10 mg/0.1 mL, 10 mg/
0.2 mL, 20 mg/0.2 mL,
20 mg/0.4 mL ...
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Bupropion For Depression
The Medical Letter on Drugs and Therapeutics • Nov 03, 1989 (Issue 804)
in about 0.1% of patients.
INTERACTIONS — Although data are limited, the manufacturer reports a higher ...
Bupropion (Wellbutrin - Burroughs Wellcome) was recently marketed in the USA for treatment of depression. First approved by the Food and Drug Administration in late 1985, the drug was withdrawn from the market in early 1986 because of a high incidence of seizures in one study.
Moricizine for Cardiac Arrhythmias
The Medical Letter on Drugs and Therapeutics • Nov 02, 1990 (Issue 830)
to two hours, and the plasma half-life following a
single dose is 1.5 to 3.5 hours. The full ...
Moricizine (mor i'; siz een) hydrochloride (Ethmozine - Du Pont), a class I antiarrhythmic drug developed in the USSR, was recently approved by the US Food and Drug Administration (FDA) for oral treatment of life-threatening ventricular arrhythmias.
Bone Marrow Transplants for Malignant Diseases
The Medical Letter on Drugs and Therapeutics • Aug 21, 1992 (Issue 877)
, Am J Clin Oncol, 14 suppl 1:S5, 1991; Medical Letter, 33:39, 1991; G Gahrton et al, N
Engl J Med ...
Intensive chemotherapy, with or without total body radiation, followed by bone marrow transplantation is now widely used in the treatment of malignant diseases. The drugs and radiation needed to try to eradicate the malignancy unavoidably destroy the bone marrow; intravenous infusion of bone marrow cells restores the marrow by repopulating it. Diseases for which bone marrow transplantation has been used include the leukemias and lymphomas, breast cancer, neuroblastoma, ovarian cancer, germ cell tumors, melanoma, multiple myeloma, and malignant gliomas (NC Gorin, Am J Clin On-col, 14...
Topical Minoxidil for Baldness: A Reappraisal
The Medical Letter on Drugs and Therapeutics • Jan 21, 1994 (Issue 914)
, 1990).
DOSAGE AND COST — The manufacturer recommends application of 1 ml twice daily,
regardless ...
Minoxidil 2% topical solution (Rogaine - Upjohn) has been available in the USA since 1988 for treatment of androgenetic alopecia (Medical Letter, 29:87, 1987). Although available only by prescription, it is advertised on television to the general public.
Extended-Release Isosorbide Mononitrate for Angina
The Medical Letter on Drugs and Therapeutics • Feb 04, 1994 (Issue 915)
1:S65,
1990; JO Parker, Can J Cardiol, 7:125, 1991). Withdrawal of the drug after one year ...
Isosorbide mononitrate, the major active metabolite of isosorbide dinitrate, was first approved in the USA for oral use in patients with chronic stable angina in 1992 (Medical Letter, 34:61, 1992). Now an extended-release formulation of isosorbide mononitrate (Imdur -Key) has been approved by the US Food and Drug Administration.
Venlafaxine - A New Antidepressant
The Medical Letter on Drugs and Therapeutics • Jun 10, 1994 (Issue 924)
. It has no affinity in vitro for cholinergic, histaminergic, or α
1
-adrenergic receptors (SA Montgomery, J Clin ...
Venlafaxine hydrochloride (Effexor - Wyeth-Ayerst) was recently approved by the US Food and Drug Administration for treatment of depression. An aminomethyl-benzyl- cyclohexanol, it is chemically related to bupropion (Wellbutrin).
Lansoprazole
The Medical Letter on Drugs and Therapeutics • Jul 21, 1995 (Issue 953)
is metabolized in the liver and
excreted in bile and urine, with a plasma half-life of about 1.5 hours ...
Lansoprazole (Prevacid -TAP), a proton pump inhibitor similar to omeprazole (Prilosec - Medical Letter, 32:19, 1990), has been approved by the US Food and Drug Administration for short-term treatment of active duodenal ulcer and erosive reflux esophagitis and for long-term treatment of chronic hypersecretory conditions, including the Zollinger-Ellison syndrome.
Melatonin
The Medical Letter on Drugs and Therapeutics • Nov 24, 1995 (Issue 962)
healthy volunteers, 0.3 or 1 mg of melatonin (Nestle, Switzerland) taken during the day produced serum ...
Several readers have asked the Medical Letter to evaluate the effectiveness and safety of exogenous melatonin for treatment of insomnia and jet lag. Melatonin has not been approved by the US Food and Drug Administration (FDA), but is available in health food stores and apparently is being used as self-medication to treat a wide variety of disorders.